nach oben

Erschienen in:

29.09.2023 | Case Report

A case of acute liver failure caused by Budd–Chiari syndrome salvaged by brain-dead donor liver transplantation

verfasst von: Kiwamu Kimura, Akihiko Osaki, Yoshihiro Hirata, Hiroto Egawa, Tomomi Kogiso, Gen Nakamura, Hideki Hashidate, Takuya Wakabayashi, Munehiro Sato, Nobuo Waguri

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

A 24-year-old man was admitted to our hospital with abdominal distension. He was found to have acute liver failure and diagnosed with Budd–Chiari syndrome based on angiography and liver biopsy. Liver transplantation was deemed necessary when angiography showed extensive thrombotic occlusion of the hepatic veins and liver biopsy revealed submassive hepatic necrosis. The patient was found to have the JAK2V617F mutation, indicating a myeloproliferative neoplasm as the background disease. He developed hepatic encephalopathy but remained conscious on on-line hemodiafiltration. Brain-dead donor liver transplantation was performed on hospital day 30. Since then, the patient has remained well.

Bansal V, Gupta P, Sinha S, et al. Budd–Chiari syndrome: imaging review. Br J Radiol. 2018;91:20180441.CrossRefPubMedPubMedCentral

Martens P, Nevens F. Budd–Chiari syndrome. United Eur Gastroenterol J. 2015;3:489–500.CrossRef

Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd–Chiari syndrome: a review by an expert panel. J Hepatol. 2003;38:364–71.CrossRefPubMed

Fujiwara K, Oda S, Abe R, et al. On-line hemodiafiltration or high-flow continuous hemodiafiltration is one of the most effective artificial liver support devices for acute liver failure in Japan. J Hepatobiliary Pancreat Sci. 2015;22:246–7.CrossRefPubMed

Yokoi T, Oda S, Shiga H, et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apheres Sci. 2009;40:61–70.CrossRef

Inoue K, Watanabe T, Maruoka N, et al. Japanese-style intensive medical care improves prognosis for acute liver failure and the perioperative management of liver transplantation. Transplant Proc. 2010;42:4109–12.CrossRefPubMed

Arata S, Tanaka K, Takayama K, et al. Treatment of hepatic encephalopathy by on-line hemodiafiltration: a case series study. BMC Emerg Med. 2010;10:1–11.CrossRef

Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd–Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–8.CrossRefPubMed

Valla DC. Primary Budd–Chiari syndrome. J Hepatol. 2009;50:195–203.CrossRefPubMed

10.

Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd–Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.CrossRefPubMed

11.

Akitomi Y, Asaoka Y, Miura R, et al. Budd–Chiari syndrome during long-term follow-up after allogeneic umbilical cord blood transplantation. Intern Med. 2022;61:1519–24.CrossRefPubMed

12.

Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:1–11.CrossRef

13.

Melear JM, Goldstein RM, Levy MF, et al. Hematologic aspects of liver transplantation for Budd–Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002;74:1090–5.CrossRefPubMed

14.

Plessier A, Valla DC. Budd–Chiari syndrome. Semin Liver Dis. 2008;28:259–69.CrossRefPubMed

15.

Lupescu IG, Dobromir C, Popa GA, et al. Spiral computed tomography and magnetic resonance angiography evaluation in Budd–Chiari syndrome. J Gastrointestin Liver Dis. 2008;17:223–6.PubMed

16.

de Franchis R. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2010;53:762–8.CrossRefPubMed

17.

Ludwig J, Hashimoto E, McGill DB, et al. Classification of hepatic venous outflow obstruction: ambiguous terminology of the Budd–Chiari syndrome. Mayo Clin Proc. 1990;65:51–5.CrossRefPubMed

18.

Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd–Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–85.CrossRefPubMedPubMedCentral

19.

Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis. 2002;22:15–26.CrossRefPubMed

20.

Terabayashi H, Okuda K, Nomura F, et al. Transformation of inferior vena caval thrombosis to membranous obstruction in a patient with the lupus anticoagulant. Gastroenterology. 1986;91:219–24.CrossRefPubMed

21.

Detry O, Roover A, Honore P, et al. Brain edema and intracranial hypertension in fulminant hepatic failure. Pathophysiology and management. World J Gastroenterol. 2006;12:7405–12.CrossRefPubMedPubMedCentral

22.

Splendiani G, Tancredi M, Daniele M, et al. Treatment of acute liver failure with hemodetoxification techniques. Int J Artif Organs. 1990;13:370–4.CrossRefPubMed

23.

Inoue K, Oda S, Abe R, et al. Practical guide on on-line hemodiafiltration for acute liver failure. Kanzo (J Japan Soc Hepatol). 2020;61:47–60.

24.

Rose CF, Amodio P, Bajaj JS, et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol. 2020;73:1526–47.CrossRefPubMed

25.

Fujiwara K, Yokosuka O, Oda S, et al. Present status of artificial liver support for acute liver failure in Japan. Kanzo (J Japan Soc Hepatol). 2012;53:530–3.

26.

Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60:715–35.CrossRefPubMed

27.

Potthoff A, Attia D, Pischke S, et al. Long-term outcome of liver transplant patients with Budd–Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35:2042–9.CrossRefPubMed

28.

Senzolo M, Cholongitas EC, Patch D, et al. Update on the classification, assessment of prognosis and therapy of Budd–Chiari syndrome. Nature clinical practice. Gastroenterol Hepatol. 2005;2:182–90.

29.

Chinnakotla S, Klintmalm GB, Kim P, et al. Long-term follow-up of liver transplantation for Budd–Chiari syndrome with antithrombotic therapy based on the etiology. Transplantation. 2011;92:341–5.CrossRefPubMed

Titel: A case of acute liver failure caused by Budd–Chiari syndrome salvaged by brain-dead donor liver transplantation
verfasst von: Kiwamu Kimura
Akihiko Osaki
Yoshihiro Hirata
Hiroto Egawa
Tomomi Kogiso
Gen Nakamura
Hideki Hashidate
Takuya Wakabayashi
Munehiro Sato
Nobuo Waguri
Publikationsdatum: 29.09.2023
Verlag: Springer Nature Singapore
Erschienen in: Clinical Journal of Gastroenterology / Ausgabe 1/2024
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-023-01863-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report

Small gastric synovial sarcoma diagnosed and treatment by laparoscopic–endoscopic cooperative surgery: a case report

Systemic AL amyloidosis with multiple submucosal hematomas of the colon: a case report and literature review

Successful prolonged treatment with sofosbuvir/velpatasvir for a hepatitis C patient with decompensated cirrhosis and treatment failure after 12-week therapy

A case of congenital biliary dilatation without pancreaticobiliary maljunction, so-called Type Ib according to Todani’s classification

A case of refractory immune checkpoint inhibitor-induced colitis improved by the treatment with vedolizumab and granulocyte–monocyte apheresis combination therapy